Tissue-nonspecific Alkaline Phosphatase (TNAP)-induced Vascular Calcification and Atherosclerosis

Information

  • Research Project
  • 9769204
  • ApplicationId
    9769204
  • Core Project Number
    R56HL131547
  • Full Project Number
    1R56HL131547-01A1
  • Serial Number
    131547
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    9/15/2018 - 6 years ago
  • Project End Date
    8/31/2019 - 5 years ago
  • Program Officer Name
    FLEG, JEROME L
  • Budget Start Date
    9/15/2018 - 6 years ago
  • Budget End Date
    8/31/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    9/10/2018 - 6 years ago

Tissue-nonspecific Alkaline Phosphatase (TNAP)-induced Vascular Calcification and Atherosclerosis

Project Summary Vascular calcification is associated with coronary artery disease and poor prognosis. This prompted us to examine whether calcification can be a pathogenic factor in atherosclerosis. We developed a mouse model, in which overexpression of tissue-nonspecific alkaline phosphatase (TNAP) in endothelial cells prompted the development of complex calcified arterial lesions that originated as macro-calcific nodules in the intima. We then tested the idea that pathologic micro-calcification can precede atherosclerosis by challenging endothelial TNAP mice with high cholesterol diet. We documented that animals with pre-existing intimal calcification developed accelerated coronary artery disease, whereas equally hyperlipidemic mice without TNAP overexpression displayed a typical course of murine atherosclerosis, in which coronary arteries were unaffected. Pharmacological inhibition of TNAP under these conditions by a specific chemical inhibitor SBI-425 reduced coronary atherosclerosis, normalized heart fraction, and improved survival. Analyzing human myocardial samples, we detected TNAP activity in the endothelium of small coronary arteries and arterioles. Our significant findings regarding TNAP, calcification and atherogenesis merit further investigation of the role of this enzyme in vascular disease. Our overall hypothesis is that under conditions that promote pathologic vascular calcification (e.g. chronic kidney disease, diabetes, and advanced age), TNAP activity might induce micro-calcification in the intima that can accelerate lipid retention and inflammation and that inhibition of TNAP activity could be a valuable therapeutic goal for the reduction of atherosclerosis in patients predisposed to vascular calcification. Here we propose to determine the prevalence of intimal micro-calcification in a large sample of individuals over the age of 65; using 250 human cadavers specimens (Aim 1.1). Going back to the animal study and using computational flow dynamics (CFD) simulations, we will compute how micro-scale endothelial roughness (experimentally determined by submicron-resolution optical scanning) affects shear stress distribution. These experiments should extend our understanding of the relationship between vascular calcification and atherogenesis associated with low shear fields ? a fundamental pathophysiological process (Aim 1.2). A potential interaction between adenosine (another product of TNAP) and alpha adrenergic signaling in the regulation of vascular tone will also be examined to explain increased sensitivity of TNAP-positive arteries to sympathomimetic stimulation and impaired relaxation (Aim 2.3). In Aim 2, we will interrogate TNAP axis in a chronic kidney disease model both genetically, by targeted deletion of TNAP in endothelial cells (Aim 2.1), and pharmacologically, by SBI-425 (Aim 2.2). Upon completion of this work we will establish that TNAP- induced vascular calcification can mechanistically precede atherosclerosis. We will also validate TNAP inhibition as a viable pharmacological approach that could potentially be used to treat many human conditions associated with both increased calcification and atherosclerosis.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R56
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
    297500
  • Indirect Cost Amount
    93541
  • Total Cost
    391041
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF OSTEOPATHIC MEDICINE
  • Funding ICs
    NHLBI:391041\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    AICS
  • Study Section Name
    Atherosclerosis and Inflammation of the Cardiovascular System Study Section
  • Organization Name
    NEW YORK INST OF TECHNOLOGY
  • Organization Department
    OTHER BASIC SCIENCES
  • Organization DUNS
    050594019
  • Organization City
    OLD WESTBURY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    115688000
  • Organization District
    UNITED STATES